174900 · KOSDAQ · ₩174900 · 앱클론
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−78.0% from the high
₩16,250Today: ₩20,500 – ₩22,350₩95,800
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Estimated leveraged-ETF rebalance on Aug 27: buy ₩19M at the close (0.3% of 20-day average trading value)
On its 31 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 2.7% of trading value and pointed the same way 4 of 31 times.
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
AbClon (앱클론, KRX: 174900) is listed on KOSDAQ, in the Biotech & Pharma sector. Abclon is a Korean biotech company founded in 2010 that develops antibody drugs and cell therapies, using its proprietary NEST antibody discovery platform, AffiMab bispecific antibody platform, and CAR-T platform. Its shares closed at ₩21,100 on Oct 28, 2026, unchanged on the day, giving it a market value of ₩421B.
Abclon is a Korean biotech company founded in 2010 that develops antibody drugs and cell therapies, using its proprietary NEST antibody discovery platform, AffiMab bispecific antibody platform, and CAR-T platform. Its lead programs include AC101, a HER2-targeting antibody for gastric and breast cancer that has been licensed to Shanghai Henlius Biotech, and AT101 (Nespe-cel), a CD19-targeting CAR-T cell therapy for blood cancers being tested in clinical trials in Korea. The company also develops AT501, a CAR-T therapy for solid tumors, and bispecific candidates AM105 and AM109, and it operates its own GMP manufacturing facility in Korea.
Written by AI from the company's latest annual report.
Predicted impact: Low· Actual: +2.5% vs sector, volume 1.1× normal (5 trading days)
Japanese patent grant for CAR-T technology; no immediate financial effect disclosed.
Predicted impact: Medium· Actual: +2.5% vs sector, volume 1.1× normal (5 trading days)
Japanese patent for a CAR-T antibody; meaningful for a pre-revenue biotech but incremental.
Titles in Korean until English translations are added.
Also known as: AbClon / 앱클론 / 174900 / KRX:174900
Source: KRX statistical information